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Abstract Cyclic adenosine diphosphoribose (cADPR) is a novel 
candidate for the mediator of Ca 2+ release from intracellular Ca ~+ 
stores. The formation of this cyclic nucleotide is catalyzed by not 
only Aplysia ADP-ribosyl cyclase but also an ecto-form enzyme 
of NAD ÷ glycohydrolase (NADase), which was previously identi- 
fied as all-trans-retinoic acid (RA)-inducible CD38 in human 
leukemic HL-60 cells. In the present study, we developed a radio- 
immunoassay specific for cADPR, by which more than 100 fmol 
of cADPR could be detected without any interference by other 
nucleotides. The possible involvement of CD38 in the formation 
of cellular cADPR was investigated with the radioimmunoassay 
method. A marked increase in cellular cADPR was accompanied 
by all-trans-RA-induced differentiation of HL-60 cells. More- 
over, a high level of cellular cADPR was observed in other leuke- 
mic cell lines, in which CD38 mRNA was expressed. Thus, CD38, 
which was initially identified as an NADase, appeared to be 
responsible for the formation of cellular cADPR. 
Key words: ADP-ribosyl cyclase; CD38 antigen; 
cyclic ADP-ribose; NAD ÷ glycohydrolase 
1. Introduction 
The cADPR-synthesizing enzyme, termed ADP-ribosyl 
cyclase, is especially abundant in Aplysia ovotestis, from which 
it was purified as a 29-kDa cytoplasmic protein and sequenced 
[14-16]. Interestingly, the ADP-ribosyl cyclase has an amino 
acid sequence homologous to that of CD38 antigen [17]. CD38 
is a 46-kDa single-transmembrane glycoprotein with a short 
N-terminal cytoplasmic domain and a long C-terminal extracel- 
lular domain [18], and its expression is widely used as a pheno- 
typic marker of the differentiation r activation of T and B 
lymphocytes [18-21]. We previously reported that ecto-form 
activity of NADase induced by all-trans-RA in HL-60 cells was 
due to the extracellular domain of CD38 [22]. Moreover, it has 
been reported that CD38 catalyzes not only the hydrolysis of 
f l -NAD +, but also the formation and hydrolysis of cyclic ADP- 
ribose to a lesser extent [23-27]. Thus, the two enzymes, which 
utilize f l -NAD + as a substrate and cleave its N-glycoside bond, 
appear to be structurally and functionally related to each other. 
In the present study, we first developed a R IA for the meas- 
urement of the cellular cADPR content. The present R IA  
method, which exhibits reasonable specificity for and sensitivity 
to cADPR with prior treatment of the sample with enzymes, 
was applied to studies on the possible involvement of CD38 in 
the formation of cellular cADPR. 
Cyclic adenosine diphosphoribose (cADPR), a metabolite of 
f l -NAD +, was first discovered in sea urchin eggs by Lee and his 
colleagues as a novel intracellular messenger with Ca2+-mobiliz - 
ing activity [1]. It is expected that the cyclic nucleotide mediates 
Ca 2+ release from an inositol 1,4,5-triphosphate-insensitive 
Ca 2+ store in sea urchin eggs [2-4]. Such Ca2+-mobilizing activ- 
ity of cADPR has also been observed in permeabilized rat 
pituitary cells [5], rat pancreatic islet t-cells [6], dorsal root 
ganglion cells [7], and a rat brain microsome fraction [8,9]. An 
increase in the cellular cADPR content was suggested in fertil- 
izing sea urchin eggs [10] and glucose-stimulated pancreatic 
islet cells [6] by bioassays of a CaZ+-releasing activity and/or the 
measurement of its amount on column chromatography [11- 
13]. However, these assays are not sufficient for precise deter- 
mination of the cellular cADPR content in terms of specificity 
and sensitivity. 
*Corresponding author. Fax: (81) (3) 3815 9604. 
Abbreviations: cADPR, cyclic adenosine diphosphoribose or cyclic 
ADP-ribose; IC5o, half-maximum inhibitory concentration; NMN +, ni- 
cotinamide mononucleotide; PCR, polymerase chain reaction; RA, all- 
trans-retinoic a id; RIA, radioimmunoassay; NADase, NAD ÷ glycohy- 
drolase. 
2. Materials and methods 
2.1. Purification fADP-ribosyl cyclase from Aplysia ovotestis and 
preparation of cADPR 
ADP-ribosyl cyclase was purified from ovotestis of Aplysia kurodai, 
a species common around the Japanese coast, as described previously 
[15,27]. cADPR was generated by incubation of the enzyme with 
,6-NAD ÷ and purified on an AG MP-1 column (Bio-Rad) as its free-acid 
form [27]. The free-acid form of cADPR (more than 98% purity) was 
converted to the sodium salt by means of chromatography on the 
sodium form of Dowex 50W X 8 (Bio-Rad), and then stored at -80 ° C. 
The structure of cADPR thus obtained was confirmed by NMR anal- 
ysis [1,28], and its biological activity was supported by an ability to 
release Ca 2÷ from the microsomal fractions of sea urchin eggs [29]. 
[32p]cADPR was also enzymatically prepared from [32P]NAD ÷ as fol- 
lows. Eighteen ¢tl of 6 ,uM [c~-32p]NAD ÷ (29.6 TBq/mmol; NEN) was 
mixed with 3/11 of the purified ADP-ribosyl cyclase (200/tg/ml) in 0.13 
M HEPES-NaOH (pH 7.4), and then the mixture was incubated at 
25°C for 4 min. The reaction was terminated by adding 2 ,ul of 50% 
(w/v) trichloroacetic acid (TCA). After the addition of 5 ,ul of a 2 M 
Tris-base solution to adjust he pH to 6-7, the sample was diluted with 
270/tl of water and then applied to the AG MP-1 column (0.4-ml bed 
volume) equilibrated with water. The column was washed with 1 ml of 
water, and bound [32p]cADPR was eluted with 30 mM trifluoroacetic 
acid. Approximately 150 ~tl of 250-300 nM [32p]cADPR was obtained, 
with recovery being more than 40%. 
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2.2. Preparation fanti-cADPR antiserum 
The purified cADPR was reacted with succinic anhydride to form the 
spacer-bound cADPR under the conditions reported previously [30], 
and the resulting succinyl cADPR was purified on the AG MP-I col- 
umn. The succinyl cADPR was then coupled with bovine serum albu- 
min (BSA) to prepare the antigen as follows. Six mg of water-soluble 
carbodiimide was added 4 times at 1-h intervals to 2 ml of 0.1 M 
Na-phosphate (pH 6.4) containing 12 mg/ml of BSA and 2 mg/ml of 
succinyl cADPR. The pH was adjusted to (~7 with HC1 or NaOH 
during the incubation at 25°C. The reaction mixture was applied to a 
gel-filtration column (50-ml bed volume; Sephacryl S-100 HR), and the 
cADPR-BSA conjugate was eluted with phosphate-buffered saline 
(PBS). Approximately 2 mol of cADPR was incorporated per mol of 
BSA under the present conditions. The cADPR-BSA conjugate, as an 
antigen (approximately 1 mg of protein), was emulsified with Freund's 
complete adjuvant and injected into rabbits. Booster injection with 1 
mg of the antigen were given five times at 2-week intervals. The immu- 
nized animals were bled by cutting acarotid artery 1 week after the last 
injection. The antiserum obtained was heated at 56°C for 30 min and 
stored at -80°C until use. 
2.3. The standard procedure of RIA for cADPR 
Crude preparations (cells or tissues) to be assayed for the cADPR 
content were mixed with a TCA solution at the final concentration f
4% and kept on ice for 20 min. After centrifugation at 15,000 x g for 
10 min, the clear supernatant was neutralized with the 2 M Tris-base 
solution at a pH of approximately 7.5 (TCA extract). The TCA extract 
was first incubated at 25°C for 2 h with 50 U/ml of bovine alkaline 
phosphatase and 2 U/ml of venom phosphodiesterase in 100 mM imi- 
dazole-HC1 (pH 7.5), 2 mM MgCI> 100 mM NaCl, and 400 mM KCI 
to degrade nucleotides that had cross-reacted with the anti-cADPR 
antiserum (see section 3). The enzyme-treated sample (or TCA extract) 
could be stored at -80°C for at least one month. For the standard RIA, 
15/.tl of a sample containing cADPR (4-512 riM) was mixed with 10 
/A of 0.3 1.5 nM [32p]cADPR (15,00(~20,000 cpm) in 0.2 M imidazole- 
HC1 (pH 7.5) containing 10 mg/ml of bovine y-globulin, followed by 
the further addition f 5/zl of the anti-cADPR antiserum diluted with 
PBS containing 15 mg/ml of bovine y-globulin. After incubation at 
25°C for 2 h, 60 ,ul of 20% (w/v) polyethylene glycol (MW; 6,000) in 
0.1 M imidazole-HC1 (pH 7.5) was added to the reaction mixture. The 
immune complex of [32p]cADPR-bound antibodies, together with 
y-globulin added as a carrier, was precipitated by centrifugation at
15,000 x g for l0 min, and the supernatant (60/zl) was counted for the 
unbound form of [32p]cADPR in a liquid-scintillation counter. 
2.4. Separation fnucleotides by A G MP-1 column chromatography 
A TCA extract prepared from cells was diluted with more than 9 
volumes of water to reduce the salt concentration, and then applied to 
and eluted from the AG MP-1 column (0.5 x 10 cm) on a HPLC system. 
Nucleotides were eluted at the flow rate of 2 ml/min with the following 
gradient of 0 mM (0%) to 150 mM trifluoroacetic a id (100%) in water; 
0% for 4 min, linear increase to 30% over 6 min, increase to 100% over 
1 min, and then holding at 100% for 2 min. The absorbance at254 nm 
was monitored. The retention times of standard nucleotides, NAD ÷, 
AMP, cADPR, and ADP-ribose, were 5.3, 5.6, 7.3, and 9.8 min, respec- 
tively, under the present conditions. 
2.5. Assay of NADase activity 
Membrane fractions obtained from HL-60 cells were incubated at 
30°C for 15 60 min with 200/zM fl-NAD + in 50/.tl of 20 mM Na- 
HEPES (pH 7.4), 1 mM MgC12, and 150 mM NaC1. The reaction was 
terminated by adding 2 ¢tl of 100% (w/v) TCA, followed by standing 
on ice for 10 rain. After centrifugation at 15,000 x g for 10 min, the clear 
supernatant was neutralized with the 2 M Tris-base solution, and then 
subjected to the AG MP-1 column as described previously [27]. 
2.6. Miscellaneous 
HL-60 cells were cultured and caused to differentiate by various 
inducers as described previously [31-33]. MOLT-4 and THP-1 were 
also cultured in RPMI-1640 supplemented with 10% fetal bovine 
serum. All-trans-retinoic acid, and bovine alkaline phosphatase (P- 
7915, Type II-G) were obtained from Sigma (MO, USA). Venom 
phosphodiesterase I (Crotalus adamanteus venom) was purchased from 
Worthington Biochemical Co. (N J, USA). Nicotinamide, succinic an- 
hydride, water-soluble carbodiimide, and polyethylene glycol (MW; 
6,000) were from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). 
Dibutyryl cAMP was from Yamasa Shouyu, Inc. (Tokyo, Japan). The 
other reagents used were of analytical grade. Protein concentrations 
were estimated with a DC Protein Assay Kit (Bio-Rad). 
3. Results 
3.1. Characterization of anti-cADPR antiserum and 
development of RIA for cADPR 
We first investigated the properties of the ant i -cADPR anti- 
serum obtained in the present study for the development of a 
R IA  for cADPR.  When 0.14).5 nM [32p]cADPR (15,000- 
20,000 cpm) was incubated at 25°C for 2 h with the antiserum 
at an appropriate dilution in a total volume of 30 ¢tl, 60-70% 
of the added [32p]cADPR bound to the antiserum. Fig. 1 shows 
the specificity of the ant i -cADPR antiserum, which was deter- 
mined from the displacement curves for various nucleotides. As 
expected, non-radiolabeled cADPR inhibited [32p]cADPR 
binding to the antiserum, with an IC5o value of 20 nM. In 
addition, NAD + and NMN ÷ inhibited the [32p]cADPR binding 
at higher concentrations; the IC5o values were both approxi- 
mately 80 ¢tM. Guanosine phosphates, uch as GTP, GDP and 
GMP, appeared to also inhibit the [32p]cADPR binding to 
lesser extents at more than 1 raM. However, the other nucleo- 
tides tested did not have an inhibitory effect at the concentra- 
t ion of 1 mM. 
Since the ant i -cADPR antiserum cross-reacted to NAD +, 
NMN ÷, and guanosine phosphates, which are possibly present 
in many types of cells and tissues at mil l imolar or submil l imolar 
concentrations, el imination of these nucleotides was required 
for precise determination of the cellular cADPR content with 
the RIA. It was noted that adenosine or guanosine had no 
inhibitory effect on the [32p]cADPR binding to the antiserum 
(see the legend to Fig. 1). Thus, enzymic conversion of the 
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Fig. 1. Specificity of the anti-cADPR antiserum for various nucleotides. 
Anti-cADPR antiserum was incubated with 0.3 nM [nP]cADPR in a 
reaction mixture (30/tl) containing various nucleotides at the final 
concentrations i dicated on the abscissa, nd [32p]cADPR bound to the 
antiserum was then measured as described in section 2.3. The 
[32p]cADPR binding to the antiserum was not inhibited by any other 
compound at concentrations of less than 1 mM. The tested compounds 
comprised ADP-ribose, ATP, ADP, AMP, adenosine, adenine, guanos- 
ine, IMP, UTP, UDP, CTP, TDP, cAMP, dibutyryl cAMP, cGMP, 
thymidine, and phosphoribose. 
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Fig. 2. Conversion of nucleotides that cross-reacted with the antiserum 
into inactive compounds. Nucleotides that cross-reacted with the anti- 
cADPR antiserum were fi st incubated at 25°C for 2 h with (hatched 
columns) or without (open columns) 50 U/ml of alkaline phosphatase 
and 2 U/ml of phosphodiesterase in 100 mM imidazole-HCl (pH 7.5), 
100 mM NaC1, 400 mM KC1, and 2 mM MgClz and then subjected to 
the standard RIA for cADPR as described in section 2.3. The final 
concentrations of nucleotides are indicated in the panel. 
cross-reactive nucleotides into inactive compounds was per- 
formed with alkaline phosphatase and phosphodiesterase. This 
enzyme treatment results in the conversion of NAD + into ni- 
cotinamide ribonucleoside and adenosine via NMN ÷ and ade- 
nosine phosphates as well as guanosine phosphates into gua- 
nosine. As shown in Fig. 2, this treatment was indeed effective 
for abolishing the inhibitory actions of NAD ÷, NMN +, and 
GTP. GDP and GMP were also inactivated by the enzyme 
treatment (data not shown). On the other hand, cADPR was 
resistant to these enzymes. Thus, more than 5 nM cADPR (i.e. 
150 fmol in a 30-/.d assay tube) could be d tected reproducibly 
without any interference by the other nucleotides so far tested. 
3.2. Accumulation of immunoreactive cADPR in HL-60 cells 
caused to differentiate by RA 
We measured cADPR content in RA-treated HL-60 cells by 
means of the RIA, since the differentiated cells expressed 
CD38, which had enzyme activities of NADase and ADP- 
ribosyl cyclase [27]. As shown in Fig. 3A, CD38 mRNA was 
specifically induced by RA in accordance with our previous 
report [22]; HL-60 cells that had been caused to differentiate 
by other inducers or undifferentiated cells did not express 
CD38 mRNA. When cADPR was extracted with TCA from 
these cells and measured by the RIA (Fig. 3B), only the RA- 
treated cells were found to contain a high concentration f the 
cyclic nucleotide (138 + 30 pmol/10 s cells). 
To confirm the increase in the cADPR content measurable 
by the RIA in RA-treated HL-60 cells, a TCA extract from the 
cells was analyzed by AG MP-1 column chromatography. The 
fractions eluted from the column were treated with alkaline 
phosphatase and phosphodiesterase nd then subjected to RIA 
for cADPR. As shown in Fig. 4, immunoreactive cADPR was 
eluted as a single peak at the same retention time as the stand- 
ard [3Ep]cADPR. Moreover, the fraction containing im- 
munoreactive cADPR exhibited CaZ+-releasing activity, when 
it was analyzed with the microsomal fraction of sea urchin eggs 
(data not shown). More than 95% of the total immunoreactive 
cADPR applied to the column was recovered at the correct 
elution position of cADPR, indicating that the present RIA for 
cADPR was reliable in terms of its specificity. 
3.3. A possible involvement of CD38 in the formation of cellular 
cADPR in leukemic ells 
The time courses of induction of CD38-NADase and cellular 
cADPR accumulation were next investigated after the addition 
of RA to HL-60 cells. As shown in Fig. 5, there was a rapid 
increase in CD38-NADase activity of plasma membrane in 
accordance with our previous report [22]; a significant level of 
the enzyme activity was observed at 12 h, and the activity 
reached a maximum level at 24 h. On the other hand, cellular 
cADPR increased gradually during the first 24-h culture and 
then rapidly after 30 h, and a high cADPR content was main- 
tained during the following culture with RA. These results, 
together with the data in Fig. 3, suggested that increase in 
cellular cADPR content is resultant from the expression of 
CD38 mRNA (and the induction of the ecto-enzyme of CD38) 
under the present conditions. Thus, we further investigated 
relationship between the expression level of CD38 mRNA and 
cellular cADPR accumulation i  other types of cells. 
As shown in Fig. 6A, the expression of CD38 mRNA was 
constitutively observed in MOLT-4 cells, a human acute lym- 
phoblastic leukemia cell line. This cell line contained a high 
level of cellular cADPR (Fig. 6B. On the other hand, THP-1 
cells, a monocytic leukemia cell line, contained a low level of 
CD38 mRNA. However, there was an increase in CD38 mRNA 
level after the cells were incubated with RA for 2 days. The 
cellular cADPR concentration i  the RA-treated THP-1 cells 
was higher than that in the non-treated ones. Thus, the increase 
in CD38 mRNA appeared to lead the cellular cADPR accumu- 
lation of cells. 
A; CD38 mRNA 
CD38--~- 
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0 
c~ ~100 
~-~50 ¢-- 
E 
_E 
0 
Treatmen~ 
B; cADPR content 
None RA Bt2-cAMP DMSO 
Fig. 3. Expression of CD38 mRNA and the cellular cADPR content 
in HL-60 cells cultured with various reagents. HL-60 cells were cultured 
without (None) or with 1 ~tM RA (RA), 0.5 mM dibutyryl cAMP 
(Bt2-cAMP), or 1.2% dimethyl sulfoxide (DMSO) for 40 h. The cells 
were washed with Krebs-Ringer buffer (minus Ca 2+) and then subjected 
for the assaying of CD38 mRNA (panel A) and the cADPR content 
(panel B). CD38 mRNA was analyzed by PCR as described previously 
[22]. The cADPR content was measured by RIA, and mean values 
obtained for three separate experiments are shown with S.E.M. 
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Fig. 4. Separation of immunoreactive cADPR by AG MP-1 column 
chromatography. Nucleotides were extracted with TCA from HL-60 
cells (2.5 x 108 cells) which had been cultured with 1 ~M RA for 40 h 
and separated by means of AG MP-1 column chromatography as
described in section 2.4. Fractions eluted from the column, after being 
treated with alkaline phosphatase and phosphodiesterase, w re sub- 
jected to the standard RIA for cADPR (e). The absorbance at254 nm 
of eluted nucleotides was also monitored ( ...... ). The elution positions 
of standard nucleotides separated under the same conditions are indi- 
cated by arrows. 
4. Discussion 
In the present study, we succeeded in developing a R IA  
method for measurement of the cellular cADPR content, by 
which more than a hundred fmol of the cyclic nucleotide could 
be specifically detected. The antiserum used in the present R IA  
exhibited high specificity for cADPR and very weak cross- 
reactivity to other nucleotides, such as NAD ÷ and NMN ÷ (see 
Fig. 1). The interference by NAD + and NMN ÷ was eliminated 
by enzyme treatment of the test samples with alkaline phos- 
phatase and phosphodiesterase, which converted the cross-re- 
active nucleotides into inactive compounds (see Fig. 2). This 
treatment will be applicable not only to the cultured cells inves- 
tigated in the present study but also to a wide variety of biolog- 
ical samples. Indeed, our preliminary results with the present 
R IA  indicated that rat brain contains approximately 200 nM 
cADPR under resting conditions (data not shown), which is the 
same value as that obtained by Lee et al. by means of a Ca 2+- 
releasing assay [11]. Moreover, there was 20-200 nM im- 
munoreactive cADPR in various tissues isolated from rats. 
We first applied this R IA  system to the measurement of the 
cellular cADPR content in RA-treated HL-60 cells, since RA 
specifically induced CD38-NADase [22], which also catalyzes 
cADPR formation from NAD +, but with lower specific activity 
[27]. Our present findings clearly indicate that there was a more 
than 20-fold increase in the cellular cADPR content of the 
differentiated HL-60 cells (see Fig. 3). If the cADPR had been 
homogeneously distributed in the cytoplasmic space of cells 
with a cell volume of 2 pl, the cellular concentration of the 
nucleotide would be approximately 1/~M. 
Our present results indicated that the expression of CD38 
mRNA resulted in increase in the cellular cADPR content in 
several types of cells. However, it is not apparent how the 
ecto-form enzyme of CD38 interacts with NAD + to generate 
cADPR inside cells. Our preliminary data suggested that the 
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Fig. 5. Time courses of the induction of NADase and the increase in 
the cellular cADPR content in RA-treated HL-60 cells. HL-60 cells 
were cultured with 1 ~M RA for the indicated times, and then the 
cADPR content (e) in the cells was measured by RIA. Membrane 
fractions were also isolated from the cultured cells for the assaying of 
NADase activity (a) as described in section 2.5. The activity is ex- 
pressed as a percentage of the maximum value, which was 60 nmol of 
nicotinamide formation/min/mg of protein. 
accumulated cADPR was not present at least in the plasma 
membranes of HL-60 cells and that activity of CD38-NADase 
could not be detected in the cytoplasmic fraction f the cells 
(data not shown). At the present ime, we can not totally rule 
out the possibility that an enzyme(s) other than CD38 is in- 
volved in the synthesis of cellular cADPR. Further studies 
would be required to elucidate the significance of CD38 as an 
effective nzyme to produce intracellular cADPR.  In any case, 
the present paper is the first showing that there is a significant 
change in the cellular cADPR content upon the differentiation 
of mammalian cells. The RIA for cADPR developed in the 
present study will facilitate studies on the physiological role of 
the new cyclic nucleotide in signal transduction. 
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Fig. 6. High levels of cellular cADPR content in cultured cells express- 
ing CD38 mRNA. MOLT-4 and THP-1 cells were cultured with (RA) 
or without (None) 1 ,uM RA for 48 h and then subjected for assaying 
of CD38 mRNA (panel A) and the cellular cADPR content (panel B) 
as described in Fig. 3. 
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